Pacira BioSciences, Inc.·Healthcare
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Healthcare
Drug Manufacturers - Specialty & Generic
788
2011-02-03
0.32

FRANK LEE AND THE BOARD HAVE OVERSEEN GROSS AND PERSISTENT UNDERPERFORMANCE FOR YEARS. WHY WOULD SHAREHOLDERS VOTE TO CONTINUE THIS UNRELENTING LACK OF TOTAL RETURN TO SHAREHOLDERS ("TRS"), WHILE ALLOWING MANAGEMENT AND THE BOARD TO FURTHER ENRICH THEMSELVES WITH TENS OF MILLIONS OF DOLLARS IN PAYOUTS?

Independent Directors, Christopher Dennis, MD, MBA, FAPA and Oliver Benton "Ben" Curtis III Outline How Their Skills and Experience Will Drive Positive Change Intend to Work Collaboratively with Incumbent Directors to Strengthen Oversight and Create Value for All Shareholders Encourage Shareholders to Support Meaningful Board Change by Voting via the WHITE Proxy Card for DOMA's Three Nominees MIAMI, May 20, 2026 /PRNewswire/ -- DOMA Perpetual Capital Management ("DOMA Perpetual") which, together with its affiliates (collectively "DOMA" or "we"), beneficially owns approximately 7.5% of the outstanding shares of common stock of Pacira BioSciences, Inc. (NASDAQ: PCRX) ("Pacira" or the "Company") announced that the two independent, highly qualified members of DOMA's three-person slate of nominees for election to the Company's board of directors have released a joint letter to Pacira stockholders. The letter can be downloaded here The full text of the letter follows: A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DIRECTOR NOMINEES CHRISTOPHER DENNIS, MD, MBA, FAPA AND OLIVER BENTON "BEN" CURTIS III May 20, 2026 Dear Pacira BioSciences shareholders, On May 5, 2026, the Pacira BioSciences, Inc. ("Pacira" or the "Company") board of directors (the "Board") mailed you a letter dismissing us as "unqualified," characterizing DOMA Perpetual Capital Management ("DOMA"), which nominated us for election to the Board, as a disruptive force, and asking you to vote for the Company's nominees using the Company's blue proxy card to preserve the status quo.

Urges Stockholders to Vote “ FOR ” the Election of Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today

PCRX remains a commercial non-opioid pain company built around Exparel, Zilretta, and Iovera. That's why I think the most important catalysts for this stock, for better or worse, will be its upcoming 2026 pipeline readouts. But I reckon that PCRX's overdependence on Exparel remains a factor worth considering, aside from other inherent biotech risks like patents and reimbursement policies, among others.

DOMA Perpetual Issues and Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement and WHITE Proxy Card - Urg

DOMA Perpetual Believes the Board and Management are Committing Gross Negligence by Misleading Investors About the True Risks the Business Faces; DOMA Contends This Conduct Constitutes a Failure of the Board's Duty of Care Maintains the Company should remove its CEO and Explore a Strategic Sale of the Company Instead of Pursuing Risky Litigation Asserts Pacira Will Continue its Value-Destroying Behavior Unless Changes are Made to the Board; DOMA's Nominees Will Bring Relevant Expertise in Risk Management and Commitment to Stockholder Value to Realign the Board with Shareholders' Interests and Creating Certainty in Outcomes Instead of Gambling with the Company's Future MIAMI, May 13, 2026 /PRNewswire/ -- DOMA Perpetual Capital Management ("DOMA Perpetual"), which, together with its affiliates (collectively, "DOMA" or "we"), beneficially owns approximately 7.5% of the outstanding shares of common stock of Pacira BioSciences, Inc. (NASDAQ: PCRX) ("Pacira" or the "Company"), has today sent a letter to the Company's stockholders outlining the rationale for urgently needed change in the composition of the Company's Board of Directors (the "Board") and emphasizing how DOMA's independent, experienced and highly qualified nominees would bring genuine independence to the Company's Board and support the much-needed maximization of stockholder value. In its letter, DOMA Perpetual asserts Management and the Board continue to promote a risky strategy of "bet the farm" litigation that has already likely cost the Company more than a third of future EXPAREL revenues in a prior settlement.